Tags: Drug.

Reslizumab is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways skin and gastrointestinal tract. As of September 2009 the drug is undergoing Phase II/III clinical trials.

ATC prefix
none

Loading...

This page contains content from the copyrighted Wikipedia article "Reslizumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.